Literature DB >> 17072195

[Systemic adverse reactions with ivermectin treatment of scabies].

A Sparsa1, J-M Bonnetblanc, I Peyrot, V Loustaud-Ratti, E Vidal, C Bédane.   

Abstract

BACKGROUND: Scabies is a common parasitic infestation and is very difficult to eradicate from institutions. Ivermectin is used extensively thanks to its efficacy and ease of use through oral administration; it was approved for the treatment of scabies in humans in 2001 in France. Most of the adverse effects noted with this drug have been seen during treatment of onchocerciasis and other filarial disease, but they are rare in the treatment of scabies. We report side effects with ivermectin in two elderly patients with scabies. CASES REPORT: A 72-year-old man was referred for scabies and was treated with benzyl benzoate (Ascabiol) and ivermectin (200 microg/kg) in a single dose. Two days later, the patient presented abdominal pain and nausea. Laboratory tests revealed cytolysis tests for other causes of hepatitis were negative. Within two weeks, liver function had returned to normal. Hepatitis due to ivermectin was diagnosed. An 86-year-old woman hospitalised for scabies was treated with benzyl benzoate and a single dose of ivermectin (200 microg/kg). She developed sinus tachycardia and asthma 3 days later. Screening for embolic, cardiac and infectious origins was found. Toxicity of ivermectin was suspected. DISCUSSION: Since the introduction of ivermectin for the treatment of scabies, reports of adverse events are rare although this drug can cause cardiac dysfunction and liver disease in other indications. In our cases, the causal relationship with ivermectin is probable and care must be taken, particularly in the elderly, the population in which this drug is probably most widely prescribed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17072195     DOI: 10.1016/s0151-9638(06)71044-4

Source DB:  PubMed          Journal:  Ann Dermatol Venereol        ISSN: 0151-9638            Impact factor:   0.777


  5 in total

Review 1.  Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19.

Authors:  Pierre Kory; Gianfranco Umberto Meduri; Joseph Varon; Jose Iglesias; Paul E Marik
Journal:  Am J Ther       Date:  2021-04-22       Impact factor: 2.688

Review 2.  The impact of SARS-CoV-2 treatment on the cardiovascular system: an updated review.

Authors:  Mohammed Ahmed Akkaif; Abubakar Sha'aban; Arturo Cesaro; Ammar Ali Saleh Jaber; Andrea Vergara; Ismaeel Yunusa; Abubakar Ibrahim Jatau; Mustapha Mohammed; G Saravana Govindasamy; Majed Ahmed Al-Mansoub; Muhamad Ali Sheikh Abdul Kader; Baharudin Ibrahim
Journal:  Inflammopharmacology       Date:  2022-06-14       Impact factor: 5.093

Review 3.  A Double-Edged Sword-Cardiovascular Concerns of Potential Anti-COVID-19 Drugs.

Authors:  Wen-Liang Yu; Han Siong Toh; Chia-Te Liao; Wei-Ting Chang
Journal:  Cardiovasc Drugs Ther       Date:  2020-06-17       Impact factor: 3.727

4.  Analysis of severe adverse effects following community-based ivermectin treatment in the Democratic Republic of Congo.

Authors:  Jean-Claude Makenga Bof; Daniel Muteba; Paul Mansiangi; Félicien Ilunga-Ilunga; Yves Coppieters
Journal:  BMC Pharmacol Toxicol       Date:  2019-08-16       Impact factor: 2.483

Review 5.  Repurposing the drug, ivermectin, in COVID-19: toxicological points of view.

Authors:  Farshad M Shirazi; Roya Mirzaei; Samaneh Nakhaee; Amir Nejatian; Shokouh Ghafari; Omid Mehrpour
Journal:  Eur J Med Res       Date:  2022-02-05       Impact factor: 2.175

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.